The modulation of CD22 in mouse models by an α2,6-sialylated glycan or an anti-CD22 antibody conjugated to an immunotoxin has been tested to eliminate B cells in cases of acute lymphoblastic leukemia. Here, CD22 is linked to acute lymphoblastic leukemia.